- Oral Chemotherapy
- Radiation Therapy
Marginal Zone Lymphoma Treatment Market was valued at USD 1,397.6 million in 2022 and it is expected to reach USD 840.2 Million by 2028, growing at a 6.2% CAGR from 2023 to 2029. Marginal zone lymphoma is a slow-growing B-cell non-Hodgkin lymphoma that begins forming from certain areas of lymph tissue. There are three regions from where it begins such as the spleen, lymph nodes, and lymphoid tissue that contains a lot of B-cells, marginal zone lymphoma is caused due to H. pylori, a helicobacter bacterium that attacks the lining of the stomach, and the first part of small intestine i.e., duodenum. The risk increases in a person of 65+ age with a weakened immune system. The treatment of marginal zone cell lymphoma is segmented into compounding chemotherapy to kill cancer cells, radiation therapy to shrink tumors, and immunotherapy. The increase in geriatric patient portal and the development of new drug development are the major factors that drive the market in the world. The global geriatric population is expected to increase in the forecast period. According to WHO, the population of the geriatric population will increase from 619 million to 1.5 billion in 2030, various possibilities are to there to infect from such types of cancer. The surge in the hospital and treatment techniques provides maximum opportunity to the hospitals, healthcare providers are launching new treatments and drugs to lower marginal zone lymphoma. The lack of skilled professionals and side effects from lymphoma treatment are major restraints in the marginal zone lymphoma treatment market. Geographically, North America and Europe hold the major market share in 2022 and are expected to dominate the lymphoma treatment market in the forecasted years.
Recent Market Key Developments:
In February 2021, The U.S. Food and Drug Administration (FDA) announced the approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody.
Fastest Growing Market
The increasing prevalence of lymphoma cancer across the world is the major driving factor in the marginal zone lymphoma treatment market during the forecast period. Lymphoma cancer is mostly seen in geriatric patients who are above 60, mainly marginal zone lymphoma affecting the small intestine and lower part of the small intestine which lowers the immune system. An increase in cancer among people enhances the large treatment market for lymphoma treatment. Hence, this will drive global market growth at a significant rate.
The marginal zone lymphoma treatment market size is USD 526 million in 2022 and it is expected to reach USD 840 billion by 2028, growing at a 6.2% CAGR from 2023 to 2029.
The leading players in the Marginal Zone Lymphoma Treatment Market are Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, Velos Bio Inc., Newave Pharmaceutical Inc., among others
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation, and Seven years forecast is presented from 2023 – 2029.